Monitoring of dabigatran and direct factor xa inhibitors in patients undergoing surgery: a prospective study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00033670

Enrollment

500

Registered

2024-03-18

Start date

2023-03-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Z92.1

Interventions

Group 1: intake of Dabigatran, Edoxaban, Rivaroxaban oder Apixaban within 48 h prior to surgery Group 2: application of low-molecular-weight heparin (LMWH)t within 48 h prior to surgery

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • all patients with factor xa inhibitor or factor xII inhibitor therapy within 48 h of last intake or unknown time of intake • patients with low molecular heparin application within 48 h before measurement • and have to undergo surgical treatment

Exclusion criteria

Exclusion criteria: • inherited bleeding disorder • briding with (low molecular) heparin

Design outcomes

Primary

Measure	Time frame
comparison between standard laboratory measurement and point-of-care monitoring	—

Secondary

Measure	Time frame
complication rate, revision, bleeding events	—

Countries

Germany

Contacts

Public ContactPeter Spieth

Universitätsklinikum Carl Gustav Carus Dresden

peter.spieth@ukdd.de+49 (0)351 458-4110

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026